Wellington Management Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Wellington Management Group’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-132,089	Closed	-$193K	–	2287
2016 Q1	$193K	Hold	132,089	–	–	﹤0.01%	2078
2015 Q4	$423K	Hold	132,089	–	–	﹤0.01%	2006
2015 Q3	$826K	Buy	+132,089	New	+$1.23M	﹤0.01%	1874
2014 Q4	–	Sell	-234,005	Closed	-$1.18M	–	2351
2014 Q3	$1.18M	Buy	+234,005	New	+$1.44M	﹤0.01%	1790

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wellington Management Group's NWBO Position: Q2 2016 in Review

Wellington Management Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 132,089 shares — an estimated $193K sold.

Wellington Management Group first reported a position in NWBO in Q3 2014 and held it in 4 quarters. The position peaked at $1.18M in Q3 2014. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

Wellington Management Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
Wellington Management Group sold 132,089 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $193K.
Wellington Management Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2014 and held it in 4 quarters.
Wellington Management Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $1.18M in Q3 2014.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on Wellington Management Group's 13F filing for Q2 2016, filed 15 Aug 2016.